ArticleCureus2025
Sepsis in a Patient With Atopic Dermatitis Following Upadacitinib Discontinuation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common chronic atopic skin condition. Severe AD may require treatment with systemic immunomodulation for disease control. Janus kinase (JAK) inhibitors such as upadacitinib are an increasingly prescribed class of immunomodulators effective for AD. However, cost and insurance coverage represent major barriers to accessing these medications. Disruptions of treatment with systemic immunomodulators predispose patients with AD to flares that can cascade into severe consequences, including sepsis. Therefore, maintenance of AD treatment is essential, and patient support programs (PSPs) offer a solution to ensure continuity of treatment. We present a case of a young adult with severe AD who lost insurance coverage and subsequently discontinued upadacitinib, leading to disease relapse complicated by cellulitis, sepsis, and acute liver failure. We highlight PSPs as an impactful solution to maintain access to AD therapy and prevent such complications in similar patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.